Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Fojo Website

Antonio Tito Fojo, M.D., Ph.D.

Selected Publications

1)  Fojo T, Bates S.
Mechanisms of resistance to PARP inhibitors--three and counting.
Cancer Discov. 3: 20-3, 2013.
2)  Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, Prchal JT, Tischler AS, Lechan RM, Zhuang Z.
New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia.
J. Clin. Oncol. [Epub ahead of print], 2013.
3)  Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT.
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
Cell Rep. 3: 277-81, 2013.
4)  Komlodi-Pasztor E, Sackett DL, Fojo T.
Tales of how great drugs were brought down by a flawed rationale--response.
Clin. Cancer Res. 19: 1304, 2013.
5)  Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE.
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Oncologist. 17: 512, 2012.
6)  Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE.
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
Clin. Cancer Res. 18: 2374-81, 2012.
7)  Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B.
Combination chemotherapy in advanced adrenocortical carcinoma.
N. Engl. J. Med. 366: 2189-97, 2012.
8)  Fojo T, Bates S, Chabner BA.
Editor's Note ...Clinical Trial Reports: A New Section.
Oncologist. 17: 11-2, 2012.
9)  Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, Mercado-Asis LB, Adams KT, Martucci V, Fojo T, Pacak K.
False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
Endocr. Relat. Cancer. 19: 83-93, 2012.
10)  Blagoev KB, Wilkerson J, Fojo T.
Hazard ratios in cancer clinical trials--a primer.
Nat Rev Clin Oncol. 9: 178-83, 2012.
11)  Komlodi-Pasztor E, Sackett DL, Fojo AT.
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.
Clin. Cancer Res. 18: 51-63, 2012.
12)  Jain M, Zhang L, He M, Patterson EE, Nilubol N, Fojo AT, Joshi B, Puri R, Kebebew E.
Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Cancer. [Epub ahead of print], 2012.
13)  Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I.
Operative management for recurrent and metastatic adrenocortical carcinoma.
J Surg Oncol. 105: 709-13, 2012.
14)  Fojo AT, Noonan A.
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox--reply to point.
Cancer Res. 72: 5150, 2012.
15)  Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T.
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.
Cell Cycle. 11: [Epub ahead of print], 2012.
16)  Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, Pacak K.
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.
N. Engl. J. Med. 367: 922-30, 2012.
17)  Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE.
Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies.
Drug Resist. Updat. 15: 50-61, 2012.
18)  Amiri-Kordestani L, Fojo T.
Why do phase III clinical trials in oncology fail so often?.
J. Natl. Cancer Inst. 104: 568-9, 2012.
19)  Fojo AT, Noonan A.
Why RECIST works and why it should stay--counterpoint.
Cancer Res. 72: 5151-7; discussion 5158, 2012.
20)  Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE.
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Clin. Cancer Res. 17: 569-80, 2011.
21)  Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M.
Delivering affordable cancer care in high-income countries.
Lancet Oncol. 12: 933-80, 2011.
22)  Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, Kiesewetter DO, Thomasson D, Morris JC, Kvetnansky R, Tischler AS, Reynolds JC, Fojo AT, Pacak K.
Increased uptake of [123I]meta-iodobenzylguanidine, [1&F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
Endocr. Relat. Cancer. 18: 143-57, 2011.
23)  Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, Avital I.
Liver resection and ablation for metastatic adrenocortical carcinoma.
Ann. Surg. Oncol. 18: 1972-9, 2011.
24)  King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, Wesley R, Lodish M, Raygada M, Gimenez-Roqueplo AP, McCormack S, Eisenhofer G, Milosevic D, Kebebew E, Stratakis CA, Pacak K.
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
J. Clin. Oncol. 29: 4137-42, 2011.
25)  Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E.
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.
Cancer. 117: 1630-9, 2011.
26)  Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T.
Mitosis is not a key target of microtubule agents in patient tumors.
Nat Rev Clin Oncol. 8: 244-50, 2011.
27)  Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE.
Phase II trial of romidepsin in patients with peripheral T-cell lymphoma.
Blood. 2011.
28)  Fojo T, Amiri-Kordestani L, Bates SE.
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
J. Natl. Cancer Inst. 103: 1738-40, 2011.
29)  Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T, Schrump DS.
Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience.
Ann. Thorac. Surg. 92: 1195-200, 2011.
30)  Sackett DL, Fojo T.
Taccalonolides: a microtubule stabilizer poses a new puzzle with old pieces.
Cell Cycle. 10: 3233-4, 2011.
31)  Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ.
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.
Chemother Res Pract. 2011: 715469, 2011.
32)  Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clin. Cancer Res. 17: 907-17, 2011.
33)  Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T.
A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.
Clin. Cancer Res. 16: 1634-41, 2010.
34)  Bates S, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey R, Turner M, Gardner E, Figg W, Steinberg S, Ling A, Fojo A, To K, Piekarz R.
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T Cell lymphoma.
Br J Hematol. 148: 256-67, 2010.
35)  Huff LM, Sackett DL, Poruchynsky MS, Fojo T.
Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells.
Cancer Res. 70: 5870-9, 2010.
36)  Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, Van Tellingen O, Bates SE, Fojo T.
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Clin. Cancer Res. 15: 3574-82, 2009.
37)  Fojo T.
From the guest editor: monitoring of therapeutic response to cancer treatment.
Cancer J. 15: 352-3, 2009.
38)  Fojo T, Grady C.
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
J. Natl. Cancer Inst. 101: 1044-8, 2009.
39)  Komlodi-Pasztor E, Trostel S, Sackett D, Poruchynsky M, Fojo T.
Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells.
Oncogene. 28: 3111-20, 2009.
40)  Veytsman I, Nieman L, Fojo T.
Management of Endocrine Manifestations and the Use of Mitotane as a Chemotherapeutic Agent for Adrenocortical Carcinoma.
J. Clin. Oncol. 27: 4619-29, 2009.
41)  Ghayee HK, Havekes B, Corssmit EP, Eisenhofer G, Hammes SR, Ahmad Z, Tessnow A, Lazúrová I, Adams KT, Fojo AT, Pacak K, Auchus RJ.
Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior.
Endocr. Relat. Cancer. 16: 291-9, 2009.
42)  Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E.
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
J. Clin. Oncol. 27: 550-6, 2009.
43)  Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
J. Clin. Oncol. 27: 5410-7, 2009.
44)  Wilkerson J, Fojo T.
Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Cancer J. 15: 379-85, 2009.
45)  Venkatesan AM, Locklin J, Lai EW, Adams KT, Fojo AT, Pacak K, Wood BJ.
Radiofrequency ablation of metastatic pheochromocytoma.
J Vasc Interv Radiol. 20: 1483-90, 2009.
46)  Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T.
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.
Cancer J. 15: 366-73, 2009.
47)  He J, Makey D, Fojo T, Adams KT, Havekes B, Eisenhofer G, Sullivan P, Lai EW, Pacak K.
Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma.
Endocrine. 36: 189-93, 2009.
48)  Hu J, Xia X, Cheng A, Wang G, Luo X, Reed MF, Fojo T, Oetting A, Gong J, Yen PM.
A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy.
Mol. Cancer Ther. 7: 3719-28, 2008.
49)  Huang H, Fojo T.
Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
J. Clin. Endocrinol. Metab. 93: 3730-2, 2008.
50)  Stein WD, Yang J, Bates SE, Fojo T.
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
Oncologist. 13: 1055-62, 2008.
51)  Fojo T.
Commentary: Novel therapies for cancer: why dirty might be better.
Oncologist. 13: 277-83, 2008.
52)  Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, Hanson JT, Wong E, Buxhoeveden N, Trepel JB, Fojo AT, Telford W, Fowler DH.
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.
J. Immunol. 180: 89-105, 2008.
53)  Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE.
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Biochem. Pharmacol. 75: 1302-12, 2008.
54)  Edgerly M, Fojo T.
Is there room for improvement in adverse event reporting in the era of targeted therapies?.
J. Natl. Cancer Inst. 100: 240-2, 2008.
55)  Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T.
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Cell Cycle. 7: 940-9, 2008.
56)  Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C.
Sorafenib-induced eruptive melanocytic lesions.
Arch Dermatol. 144: 820-2, 2008.
57)  Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T.
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.
Cancer. 113: 2020-8, 2008.
58)  Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T.
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
Oncologist. 13: 1046-54, 2008.
59)  Stein WD, Litman T, Fojo T, Bates SE.
A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patients.
Biochim. Biophys. Acta. 1770: 857-71, 2007.
60)  Zhuang SH, Hung YE, Hung L, Robey RW, Sackett DL, Linehan WM, Bates SE, Fojo T, Poruchynsky MS.
Evidence for microtubule target engagement in tumors of patients receiving ixabepilone.
Clin. Cancer Res. 13: 7480-6, 2007.
61)  Rixe O, Fojo T.
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?.
Clin. Cancer Res. 13: 7280-7, 2007.
62)  Fojo T, Menefee M.
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Ann. Oncol. 18 Suppl 5: v3-8, 2007.
63)  Fojo T.
Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.
Drug Resist. Updat. 10: 59-67, 2007.
64)  Goldsmith ME, Aguila A, Steadman K, Martinez A, Steinberg SM, Alley MC, Waud WR, Bates SE, Fojo T.
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Mol. Cancer Ther. 6: 496-505, 2007.
65)  Fojo T, Coley HM.
The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies.
Clin. Breast Cancer. 7: 749-56, 2007.
66)  Fojo T.
Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?.
J. Natl. Cancer Inst. 98: 1345-7, 2006.
67)  Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE.
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
Clin. Cancer Res. 12: 3762-73, 2006.
68)  Bates SE, Rosing DR, Fojo T, Piekarz RL.
Challenges of evaluating the cardiac effects of anticancer agents.
Clin. Cancer Res. 12: 3871-4, 2006.
69)  Huff LM, Lee J, Robey RW, Fojo T.
Characterization of gene rearrangements leading to activation of MDR- 1.
J Biol Chem. 281: 36501-9, 2006.
70)  Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE.
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
Clin. Cancer Res. 12: 1547-55, 2006.
71)  Trostel SY, Sackett DL, Fojo T.
Oligomerization of p53 Precedes its Association with Dynein and Nuclear Accumulation.
Cell Cycle. 5: 2253-9, 2006.
72)  Niederhuber JE, Fojo T.
Treatment of metastatic disease in patients with neuroendocrine tumors.
Surg. Oncol. Clin. N. Am. 15: 511-33, viii, 2006.
73)  Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T.
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Cancer. 103: 1932-8, 2005.
74)  Huff LM, Wang Z, Iglesias A, Fojo T, Lee JS.
Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples.
Cancer Res. 65: 11694-703, 2005.
75)  Demidenko ZN, Fojo T, Blagosklonny MV.
Complementation of two mutant p53: implications for loss of heterozygosity in cancer.
FEBS Lett. 579: 2231-5, 2005.
76)  Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T.
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.
Cancer Res. 65: 7386-92, 2005.
77)  Stein WD, Litman T, Fojo T, Bates SE.
Differential expression of cell adhesion genes: implications for drug resistance.
Int. J. Cancer. 113: 861-5, 2005.
78)  Ma ES, Bates WD, Edmunds A, Kelland LR, Fojo T, Farrell N.
Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile.
J. Med. Chem. 48: 5651-4, 2005.
79)  Bates SE, Fojo T.
Epidermal growth factor receptor inhibitors: a moving target?.
Clin. Cancer Res. 11: 7203-5, 2005.
80)  Chen KG, Wang YC, Schaner ME, Francisco B, Durán GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI.
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.
Cancer Res. 65: 9388-97, 2005.
81)  Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG.
Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Crit. Rev. Oncol. Hematol. 53: 25-34, 2005.
82)  Fojo AT.
Introduction: chemotherapies in the treatment of breast cancer.
Semin. Oncol. 32: S1-2, 2005.
83)  Fojo AT, Menefee M.
Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).
Semin. Oncol. 32: S3-8, 2005.
84)  Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM.
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
J Clin Oncol. 23: 2726-34, 2005.
85)  Neeman Z, Sarin S, Coleman J, Fojo T, Wood BJ.
Radiofrequency ablation for tumor-related massive hematuria.
Journal of vascular and interventional radiology : JVIR. 16: 417-21, 2005.
86)  Rao VK, Knutsen T, Ried T, Wangsa D, Flynn BM, Langham G, Egorin MJ, Cole D, Balis F, Steinberg SM, Bates S, Fojo T.
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Mutat Res. 583: 105-19, 2005.
87)  Dean M, Fojo T, Bates S.
Tumour stem cells and drug resistance.
Nat Rev Cancer. 5: 275-84, 2005.
88)  Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T.
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Clin Cancer Res. 10: 4724-33, 2004.
89)  Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T.
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Clin Cancer Res. 10: 4724-33, 2004.
90)  Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T.
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Biochemistry. 43: 13944-54, 2004.
91)  Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, Fojo T, Chen CC.
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Clin Cancer Res. 9: 650-6, 2003.
92)  Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T.
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
J Clin Oncol. 21: 1866-73, 2003.
93)  Hiroi N, Kino T, Bassett M, Rainey WE, Phung M, Abu-Asab M, Fojo T, Briata P, Chrousos GP, Bornstein SR.
Pituitary homeobox factor 1, a novel transcription factor in the adrenal regulating steroid 11beta-hydroxylase.
Horm Metab Res. 35: 273-8, 2003.
94)  Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T.
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases.
Cancer. 97: 554-60, 2003.
95)  Fojo T, Bates S.
Strategies for reversing drug resistance.
Oncogene. 22: 7512-23, 2003.
96)  Agrawal M, Edgerly M, Fojo T, Kotz H.
Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog.
Gynecol Oncol. 90: 96-9, 2003.
97)  Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T.
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma.
Cancer. 94(9): 2333-2343, 2002.
98)  Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T.
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Cancer. 94: 2333-43, 2002.
99)  Kitazono M, Chuman Y, Aikou T, Fojo T.
Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cAMP pathway.
Int J Cancer. 99(3): 453-459, 2002.
100)  Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI.
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
Mol Cancer Ther. 1: 215-25, 2002.
101)  Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, Greber UF, Fojo T.
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics.
Proc Natl Acad Sci U S A. 99: 10855-60, 2002.
102)  Kitazono M, Rao VK, Robey R, Aikou T, Bates S, Fojo T, Goldsmith ME.
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.
Blood. 99(6): 2248-2251, 2002.
103)  Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE.
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.
Molec Cancer Therap. 1: 937-941, 2002.
104)  Blagosklonny MV, Demidenko ZN, Fojo T.
Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity.
Cell Cycle. 1: 67-74, 2002.
105)  Gottesman MM, Fojo T, Bates SE.
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nature Rev Cancer. 2(1): 48-58, 2002.
106)  Fojo T.
p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53.
Drug Resist Updat. 5: 209-16, 2002.
107)  Blagosklonny MV, Robey R, Sheikh MS, Fojo T.
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death.
Cancer Bio & Therapy. 1(2): 113-117, 2002.
108)  Wood BJ, Fojo T, Walther MM, Libutti SK.
Percutaneous tumor ablation with radiofrequency.
Cancer. 94(2): 443-451, 2002.
109)  Sandor V, Fojo AT, Robey R, Bakke S, Tucker E, Kang MH, Figg WD, Chan KK, Sausville E, Goldspiel B, Balcerzak SP, Bates SE.
Phase I Trial of a Novel Antitumor Depsipeptide (FR 901228) in Patients with Refractory Neoplasms.
Clin Cancer Res. 8(3): 718-728, 2002.
110)  Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T.
Reversal of multidrug resistance: lessons from clinical oncology.
Novartis Found Symp. 243: 283-296, 2002.
111)  Kitazono M, Bates S, Fok P, Fojo T, Blagosklonny MV.
The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53.
Cancer Biol Ther. 1: 665-8, 2002.
112)  Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S.
A Phase I Study of Infusional Paclitaxel in Combination with the PgP Antagonist PSC833.
J Clin Oncol. 19(3): 832-842, 2001.
113)  Bates S, Bakke S, Kang M, Golspiel B, Meadows B, Choyke P, Merino M, Chen C, Robey R, Lemon S, Chico I, Smith T, Bergan R, Figg WD, Fojo T.
A Phase I Study of Infusional Vinblastine in Combination with the Pgp Antagonist PSC 833 (Valdospar).
Cancer. 92: 1577-1590, 2001.
114)  Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM.
The Hsp90 Inhibitor Geldanamycin Selectively Sensitizes Bcr-Abl-expressing Leukemia Cells to Cytotoxic Chemotherapy.
Leukemia. 15: 1537-1543, 2001.
115)  Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE.
The p-glycoprotein antagonist psc 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Clin Cancer Res. 7: 1610-1617, 2001.
116)  Sandor V, Fojo T, Bates SE.
Future perspectives for the development of P-glycoprotein modulators.
Drug Resist. Updat. 1: 190-200, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/9/2013.